EGFR and prostate carcinoma: In the analysis, the most enriched pathways were maturity-onset diabetes of the young (MODY), EGFR tyrosine kinase inhibitor resistance, pancreatic cancer, insulin secretion, small cell lung cancer, prostate cancer, transcriptional misregulation in cancer, HIF-1 (Hypoxia-inducible factor 1) signaling pathway, the PI3K-Akt (Phosphoinositide 3-kinases-protein kinase B) signaling pathway, and human papillomavirus infection (Table 1).